2. Peptides
  3. Peptide and Derivatives
  4. β-Amyloid and Tau Peptides
  5. β-Amyloid Peptides

β-Amyloid Peptides

Custom Peptide Synthesis

β-Amyloid peptides (Aβ) are short-chain peptides generated by enzymatic cleavage of amyloid precursor protein (APP). They tend to form β-sheet conformations and aggregates into amyloid plaques, which represent a key pathological hallmark and contributing factor in Alzheimer’s disease.

β-Amyloid Peptides (125):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0128
    β-Amyloid (25-35) 131602-53-4 99.84%
    β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
    β-Amyloid (25-35)
  • HY-P1363
    β-Amyloid (1-42), human TFA 99.66%
    β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death.
    β-Amyloid (1-42), human TFA
  • HY-P1363A
    β-Amyloid (1-42), human 107761-42-2 99.89%
    β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 ℃, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 ℃ to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death.
    β-Amyloid (1-42), human
  • HY-P1388
    β-Amyloid (1-42), (rat/mouse) 166090-74-0 98.82%
    β-Amyloid (1-42), (rat/mouse) is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.
    β-Amyloid (1-42), (rat/mouse)
  • HY-P1363B
    β-Amyloid (1-42), human, HFIP-treated 107761-42-2 99.89%
    β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from β-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death.
    β-Amyloid (1-42), human, HFIP-treated
  • HY-P3688A
    β-Amyloid (1-38) TFA
    β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans.
    β-Amyloid (1-38) TFA
  • HY-P0265C
    β-Amyloid (1-40), HFIP-treated TFA
    β-Amyloid (1-40), HFIP-treated is a β-Amyloid (1-40) (HY-P0265A) treated with HFIP. β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease.
    β-Amyloid (1-40), HFIP-treated TFA
  • HY-P4867A
    β Amyloid (1-42) (scrambled) TFA
    β Amyloid (1-42) (scrambled) TFA is a negative control of β-Amyloid (1-42), human TFA (HY-P1363).
    β Amyloid (1-42) (scrambled) TFA
  • HY-P1362
    β-Amyloid (42-1), human 317366-82-8 99.88%
    β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). Its active form, β-Amyloid (1-42), may play a key role in the pathogenesis of Alzheimer's disease.
    β-Amyloid (42-1), human
  • HY-P0265A
    β-Amyloid (1-40) (human) TFA 99.89%
    β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease.
    β-Amyloid (1-40) (human) TFA
  • HY-P1363F3
    5-FAM-β-Amyloid (1-42), human Tris
    5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a5-FAM labeled β-Amyloid (1-42), human TFA (HY-P1363).
    5-FAM-β-Amyloid (1-42), human Tris
  • HY-P1388A
    β-Amyloid (1-42), (rat/mouse) TFA 98.26%
    β-Amyloid (1-42), (rat/mouse) TFA is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.
    β-Amyloid (1-42), (rat/mouse) TFA
  • HY-P4882A
    (Pyr3)-Amyloid β-Protein (3-42) (TFA) 98.20%
    (Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits.
    (Pyr3)-Amyloid β-Protein (3-42) (TFA)
  • HY-P2550A
    β-Amyloid (1-40), FAM-labeled TFA 99.71%
    β-Amyloid (1-40), FAM-labeled TFA is a FAM fluorescently-labelled β-Amyloid (1-40) peptide (λex= 492 nm and λem= 518 nm).
    β-Amyloid (1-40), FAM-labeled TFA
  • HY-P5124
    β-Amyloid peptide(16-20) 153247-40-6 99.95%
    β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of Amyloid-β (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH2 residues added at N- and C-terminal ends to aid solubility).
    β-Amyloid peptide(16-20)
  • HY-P5905
    Citrullinated amyloid-β (1-42) peptide (human)
    Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets.
    Citrullinated amyloid-β (1-42) peptide (human)
  • HY-P1466
    β-Amyloid (1-16) 131580-10-4 99.98%
    β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-16)
  • HY-P3908
    FITC-β-Ala-Amyloid β-Protein (1-42) ammonium 99.36%
    FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease.
    FITC-β-Ala-Amyloid β-Protein (1-42) ammonium
  • HY-P1903
    β-Amyloid (35-42) 183292-41-3 98.69%
    β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.
    β-Amyloid (35-42)
  • HY-P0128A
    β-Amyloid (25-35), HFIP-treated 131602-53-4 99.71%
    β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
    β-Amyloid (25-35), HFIP-treated